Last reviewed · How we verify
Protopic® 0.1% ointment
At a glance
| Generic name | Protopic® 0.1% ointment |
|---|---|
| Also known as | Protopic®, Tacrolimus ointment 0.1% |
| Sponsor | BioCis Pharma Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of 308-nm Excimer Lamp Combined With Tacrolimus vs Tacrolimus as Monotherapy in Treating Vitiligo on Children (NA)
- Comparison of Lindioil (Indigo Naturalis Oil Extract) Ointment to Protopic® Ointment 0.1% in Treating Atopic Dermatitis (PHASE2)
- Efficacy and Safety of a 0.1% Tacrolimus Nasal Ointment as a Treatment for Epistaxis in Hemorrhagic Hereditary Telangiectasia (HHT) (PHASE2)
- To Study Generic Tacrolimus Ointment, 0.1% in the Treatment of Moderate to Severe Atopic Dermatitis (Inflammation of Skin: Itchy, Red, Swollen, and Cracked Skin) (PHASE3)
- A Phase I Study to Assess Novel Ointment in a Psoriasis Plaque Test (PHASE1)
- Tacrolimus Ointment Interest (PROTOPIC ®) in the Maintenance Treatment of Severe Seborrheic Dermatitis (PHASE3)
- Treatment and Control of Atopic Dermatitis With 0.1% Tacrolimus Ointment (PHASE3)
- Protopic Ointment in Adult Atopic Eczema of the Face (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Protopic® 0.1% ointment CI brief — competitive landscape report
- Protopic® 0.1% ointment updates RSS · CI watch RSS
- BioCis Pharma Ltd portfolio CI